2.965EUR+4.04%Mkt Cap: 55.87M EURP/E: —Last update: 2026-06-01
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in p…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap55.87M EUR
Enterprise Value46.28M EUR
Revenue (TTM)4.52M EUR
Gross Profit1.97M EUR
Net Income (TTM)-28.90M EUR
Revenue/Share0.2840 EUR
Last Price2.965 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees52
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012634822
Valuation
P/E (Trailing)—
P/E (Forward)-2.56
PEG—
EV/EBITDA-1.57
EV/Revenue10.23
P/S11.87
P/B29.69
EPS (TTM)-2.15
EPS (Forward)-1.11
52W Range
2.6006% of range8.620
52W High8.620 EUR
52W Low2.600 EUR
Profitability
Gross Margin61.13%
Oper. Margin-714.35%
EBITDA Margin0.00%
Profit Margin-898.76%
ROE-279.64%
ROA-75.07%
Growth
Revenue Growth40.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.04M EUR
CapEx (TTM)753.00K EUR
FCF Margin-313.01%
FCF Yield-25.35%
Net Debt-7.43M EUR
Net Debt/EBITDA0.25
Balance Sheet
Debt/Equity1.54
Current Ratio1.94
Quick Ratio1.87
Book Value/Sh0.0960 EUR
Cash/Share1.320 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)10.00 EUR
Target Range3.000 EUR – 17.00 EUR
# Analysts3
Ownership
Shares Out.18.84M
Float9.87M
Insiders22.10%
Institutions48.62%
Technical
SMA 505.781 (-48.7%)
SMA 2005.275 (-43.8%)
Beta0.46
S&P 52W Chg27.94%
Avg Vol (30d)152.83K
Avg Vol (10d)258.05K
Technical Indicators
RSI (14)24.5
MACD-0.9046
MACD Signal-0.4904
MACD Hist.-0.4142
BB Upper9.262 EUR
BB Middle5.436 EUR
BB Lower1.610 EUR
BB Width140.77%
ATR (14)0.5224 EUR
Vol Ratio (20d)0.77x